Abstract
Background. Hepatitis C infection is a major reason for long-standing liver disorder with direct-acting antivirals were allowed for its treatment. Few studies aimed to assess pulmonary complications of direct acting antiviral. Purpose. This trial was conducted to assess the lung parenchymal affection in hepatitis C patients before and after three months treatment with oral (Direct) antiviral drugs (Sofospovir, Daclatasvir and Ribavirin). Methods. the study was conducted on 30 outpatient patients, Kasr El-Aini & Nasser Institute Hospital, Cairo, from April 2016 to December 2017. Patients were randomly allocated into two equal groups using computerized randomization software: Group A (study group): 15 patients that received oral antiviral drugs (Sofospuvir, Daclatasvir and Ribavirin) plus multivitamins for 3 months and Group B (control group): 15 patients received multivitamins drugs only for 3 months. Serology for HCV, HRCT were measured to ensure inclusion of the patient. Pulmonary function testing, diffusing capacity (DLCO) and carbon monoxide and Viremia testing were conducted to show effect of treatment. Results. There was statistically significant increase in the FEV1, FVC, DLCO SB, FEV1/FVC, and DLCO/VA after 3 months treatment course in study group. While control group showed significant increase in FEV1/FVC and significant worse in DLCO/VA after 3 months. As regard comparison of pulmonary function variables as well as % of its changes between two groups, study group showed significant increase in DLCO/VA (post) after 3 months treatment course. Conclusion. Oral Antiviral treatment was associated with improvement in pulmonary function. However, larger multicenter reports are needed for more evaluation.

Key words:
Hepatitis C, Direct-acting antiviral, DLCO